Chapter
Licensed
Unlicensed
Requires Authentication
CHAPTER 8. Chemotherapy-Induced Cardiomyopathy
-
Edo Y. Birati
You are currently not able to access this content.
You are currently not able to access this content.
Chapters in this book
- Frontmatter i
- Contents v
- Contributors ix
- The Concept of Iatrogenicity 1
-
PART I. Medical Harm
- CHAPTER 1. Iatrogenicity: Definition, History, and Modern Context 5
- CHAPTER 2. Epidemiology and Public Health Aspects and Implications of Iatrogenicity: Regulatory, Legal and Ethical Dimensions 16
- CHAPTER 3. Risk Management: The Medical Center Administration Perspective 22
- CHAPTER 4. Iatrogenicity from the Patient’s Perspective 28
- CHAPTER 5. A Naturopathic Perspective on Iatrogenesis 34
-
PART II. Iatrogenicity of Cardiovascular Drugs and Cardiovascular Toxicity of Noncardiac Drugs
- CHAPTER 6. Clinical Manifestations of Acute and Chronic Drug-Induced Iatrogenic Cardiovascular Diseases and Syndromes 47
- CHAPTER 7. Drug-Induced Cardiac Arrhythmias and Sudden Cardiac Death 62
- CHAPTER 8. Chemotherapy-Induced Cardiomyopathy 77
- CHAPTER 9. Iatrogenicity of Blood Pressure Measurement in the Diagnosis of Hypertension 88
- CHAPTER 10. Antihypertensive Drug–Induced Iatrogenic Cardiovascular Syndromes 101
- CHAPTER 11. Iatrogenicity of Cardiovascular Drugs Associated With Cardiac and Noncardiac Toxicities: Antihypertensive Agents and Biologics 116
- CHAPTER 12. Iatrogenic Aspects of Hypertension in Pregnancy: Focus on Preeclampsia 143
- CHAPTER 13 Women and Iatrogenic Cardiovascular Disease: Menopausal Estrogen as the Prime Suspect 156
- CHAPTER 14. Iatrogenic Aspects of Lipid-Lowering, Antiplatelet, and Anticoagulant Agents 163
- CHAPTER 15. Iatrogenic Effects of Urologic Drugs on the Cardiovascular System 175
- CHAPTER 16. Iatrogenicity and Antianginal Drugs 188
- CHAPTER 17. Antidiabetic Drugs and Cardiovascular Risk: Where Do We Stand? 194
- CHAPTER 18. Cardiovascular Iatrogenicity in Older Adults 205
-
PART III. Iatrogenicity of Diagnostic and Therapeutic, Invasive and Noninvasive Cardiovascular Interventions, Devices, and Surgeries
- CHAPTER 19. Iatrogenic Aspects of Noninvasive and Invasive Diagnostic Methods in Interventional Cardiology 221
- CHAPTER 20. Iatrogenicity Associated With Interventional Treatment Modalities in Cardiology 233
- CHAPTER 21. Iatrogenicity of Diagnostic and Therapeutic, Invasive and Noninvasive Cardiovascular Interventions, Devices, and Surgeries 243
- CHAPTER 22. Iatrogenic Aspects of Cardiac Electrophysiology 255
- CHAPTER 23. Iatrogenic Aspects in Cardiac Device 271
- CHAPTER 24. Cardiovascular Iatrogenicity of Respiratory Therapeutic Modalities 287
-
PART IV. Iatrogenic Aspects of Sport Cardiology and Lifestyle Modifications
- CHAPTER 25. Trained Athletes 309
- CHAPTER 26. Sports Cardiology 318
- CHAPTER 27. Dangers of Lifestyle Modification Advice 327
-
PART V. Iatrogenicity of Dietary Supplements, Herbal Products, and Other Nontraditional Therapies in Cardiovascular Medicine
- CHAPTER 28. Safety of Dietary and Herbal Supplements: Side Effects and Contraindications 337
- CHAPTER 29. Interactions Between Supplements and Medications 370
- Index 415
Chapters in this book
- Frontmatter i
- Contents v
- Contributors ix
- The Concept of Iatrogenicity 1
-
PART I. Medical Harm
- CHAPTER 1. Iatrogenicity: Definition, History, and Modern Context 5
- CHAPTER 2. Epidemiology and Public Health Aspects and Implications of Iatrogenicity: Regulatory, Legal and Ethical Dimensions 16
- CHAPTER 3. Risk Management: The Medical Center Administration Perspective 22
- CHAPTER 4. Iatrogenicity from the Patient’s Perspective 28
- CHAPTER 5. A Naturopathic Perspective on Iatrogenesis 34
-
PART II. Iatrogenicity of Cardiovascular Drugs and Cardiovascular Toxicity of Noncardiac Drugs
- CHAPTER 6. Clinical Manifestations of Acute and Chronic Drug-Induced Iatrogenic Cardiovascular Diseases and Syndromes 47
- CHAPTER 7. Drug-Induced Cardiac Arrhythmias and Sudden Cardiac Death 62
- CHAPTER 8. Chemotherapy-Induced Cardiomyopathy 77
- CHAPTER 9. Iatrogenicity of Blood Pressure Measurement in the Diagnosis of Hypertension 88
- CHAPTER 10. Antihypertensive Drug–Induced Iatrogenic Cardiovascular Syndromes 101
- CHAPTER 11. Iatrogenicity of Cardiovascular Drugs Associated With Cardiac and Noncardiac Toxicities: Antihypertensive Agents and Biologics 116
- CHAPTER 12. Iatrogenic Aspects of Hypertension in Pregnancy: Focus on Preeclampsia 143
- CHAPTER 13 Women and Iatrogenic Cardiovascular Disease: Menopausal Estrogen as the Prime Suspect 156
- CHAPTER 14. Iatrogenic Aspects of Lipid-Lowering, Antiplatelet, and Anticoagulant Agents 163
- CHAPTER 15. Iatrogenic Effects of Urologic Drugs on the Cardiovascular System 175
- CHAPTER 16. Iatrogenicity and Antianginal Drugs 188
- CHAPTER 17. Antidiabetic Drugs and Cardiovascular Risk: Where Do We Stand? 194
- CHAPTER 18. Cardiovascular Iatrogenicity in Older Adults 205
-
PART III. Iatrogenicity of Diagnostic and Therapeutic, Invasive and Noninvasive Cardiovascular Interventions, Devices, and Surgeries
- CHAPTER 19. Iatrogenic Aspects of Noninvasive and Invasive Diagnostic Methods in Interventional Cardiology 221
- CHAPTER 20. Iatrogenicity Associated With Interventional Treatment Modalities in Cardiology 233
- CHAPTER 21. Iatrogenicity of Diagnostic and Therapeutic, Invasive and Noninvasive Cardiovascular Interventions, Devices, and Surgeries 243
- CHAPTER 22. Iatrogenic Aspects of Cardiac Electrophysiology 255
- CHAPTER 23. Iatrogenic Aspects in Cardiac Device 271
- CHAPTER 24. Cardiovascular Iatrogenicity of Respiratory Therapeutic Modalities 287
-
PART IV. Iatrogenic Aspects of Sport Cardiology and Lifestyle Modifications
- CHAPTER 25. Trained Athletes 309
- CHAPTER 26. Sports Cardiology 318
- CHAPTER 27. Dangers of Lifestyle Modification Advice 327
-
PART V. Iatrogenicity of Dietary Supplements, Herbal Products, and Other Nontraditional Therapies in Cardiovascular Medicine
- CHAPTER 28. Safety of Dietary and Herbal Supplements: Side Effects and Contraindications 337
- CHAPTER 29. Interactions Between Supplements and Medications 370
- Index 415